CoChat

The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review

Open access
Pîntea, Alexandru-Ioan, Croitoru, Adina Emilia, Dinu-Pîrvu, Cristina Elena, Dima, Simona Olimpia · 2026 · Frontiers in Pharmacology

The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index; 68 of the 113 sources its claims cite were checked for support.

Abstract

Introduction: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive and invasive malignancies, with limited response to the currently available systemic therapy options. Having a 5-year survival of 12%, there is a serious need for novel therapeutic options, including drug repurposing for the treatment of PDAC. In recent years, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) inhibitors, also known as statins, have been identified as potential candidates for PDAC therapy repurposing. Methods: We have performed a scoping literature review to summarize the extent of knowledge on statins' effects on PDAC, both in clinical studies and preclinical models, and to explain the mechanisms underlying statins' antiproliferative effect on PDAC. We have followed the PRISMA Extension for Scoping Reviews (PRISMA-ScR) guidelines. We have searched PubMed and Web of Science for original articles published between January 2021 and January 2026. Results: Our review systematically linked the clinical outcomes, molecular mechanism, and tumor microenvironment in PDAC-statin research. Clinical studies of the correlation between statin treatment and PDAC incidence yielded mixed results. Among the mechanisms we have summarized are disruption of the plasma membrane lipid rafts, reduction of protein prenylation, increase of the tumor immunogenicity, reduction of signaling, both RAS-mediated and by alternative pathways, and disruption of mitochondrial respiration. Statins also showed synergistic effects with chemotherapeutic agents including gemcitabine, 5-fluorouracil, and oxaliplatin in preclinical models. Discussion: Despite promising preclinical data, the clinical evidence remains limited to observational studies and a single phase 2 trial. Randomized controlled trials with biomarker-driven patient selection are needed to establish the role of statins as adjuvant therapy in PDAC.

Overview

CoChat Summary

TL;DR

This scoping review maps 2021–2026 evidence on statins in pancreatic ductal adenocarcinoma (PDAC), linking mixed clinical outcomes with convergent preclinical mechanisms. It concludes that preclinical antitumor signals are promising, but clinical evidence remains preliminary and insufficient to support statins as antitumor therapy in PDAC.

Key findings

  • Clinical evidence is mixed: PDAC incidence studies reported increased risk with >5 years statin use (HR 1.77, 95% CI 1.16–2.70, p = 0.04), no impact (HR 0.98, 95% CI 0.61–1.60), and reduced incidence in an ILD/pulmonary fibrosis cohort (adjusted HR 0.42, 95% CI 0.29–0.63).
  • Survival studies showed mostly positive but non-uniform signals: post-diagnosis statin use was associated with improved OS (e.g., HR 0.86, 95% CI 0.76–0.97; duration categories with p-trend = 0.04), while preoperative statin use in one multicentric cohort showed no significant OS or DFS benefit.
  • The only reported clinical trial, single-arm phase 2 NCT06241352, enrolled 42 locally advanced/metastatic PDAC patients receiving atorvastatin 80 mg/day with chemotherapy; ≥20% CA19-9 reduction occurred in 70.3%, with median PFS 8.05 months.
  • Preclinical studies identified multiple mechanisms: mevalonate pathway inhibition, reduced KRAS prenylation, lipid raft disruption, YAP/TAZ downregulation, PD-L1 reduction, immune microenvironment remodeling, mitochondrial dysfunction, and synergy with gemcitabine, 5-fluorouracil, and oxaliplatin.

Methods

  • Scoping review following PRISMA-ScR, with a prewritten protocol and PCC framework; PubMed and Web of Science were searched for original articles published from January 2021 to January 2026.
  • Inclusion criteria covered PDAC patients, cancer-free subjects, or human PDAC preclinical models treated with statins; exclusions included reviews, meta-analyses, conference abstracts, non-PDAC, non-human models, no statin intervention, older articles, and non-English articles.
  • From 135 records, 16 duplicates were removed, 67 records were removed at title/abstract screening, 4 full texts were unavailable, 20 full texts were excluded, and 28 reports were included; data were charted independently by two reviewers and synthesized narratively.

Limitations

  • The paper states that limiting the search to the past 5 years risks excluding older relevant studies, and that only PubMed and Web of Science were searched.
  • The paper states that data heterogeneity prevented meta-analysis, the scoping review design did not include formal quality assessment of individual studies, and clinical evidence is predominantly observational while many preclinical studies used supraphysiological statin concentrations.
  • Evident from the text: the clinical evidence includes contradictory observational findings and only one single-arm phase 2 trial, with no randomized controlled trial data; the review also notes no study has quantified intratumoral statin concentrations in PDAC.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fphar.2026.1815366

Cites

50 of 51 references verified0 citation errors · 1 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE 1 The PRISMA flow diagram.
FIGURE 1 The PRISMA flow diagram.CC BY · PubMed Central
FIGURE 2 The intracellular mechanisms of action of statins in the PDAC cell (created with biorender.com Accessed on March 2026).
FIGURE 2 The intracellular mechanisms of action of statins in the PDAC cell (created with biorender.com Accessed on March 2026).CC BY · PubMed Central

Verification

Claims the paper makes

64 Valid · 1 Not valid · 42 Not checked · 44 Own results and interpretations

89 more claims · 41 with their cited sources checked

Create a free account to see all 151 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 17
  • It may state two separate claims as one. 45
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 51 references

Metadata

Authors
Pîntea, A.-I., Croitoru, A. E., Dinu-Pîrvu, C. E., & Dima, S. O.
Affiliations
  • Fundeni Clinical Institute
  • Carol Davila University of Medicine and Pharmacy (RO)
  • Carol Davila University of Medicine and Pharmacy
Venue
Frontiers in Pharmacology
Published
2026-04-29
Volume
17
Pages
1815366-1815366
ISSN
1663-9812 (ISSN-L)
OpenAlex
W7159833774
Cited by
0
References
50
FWCI
0.00
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
statins, pancreatic ductal adenocarcinoma, drug repurposing, HMGCR inhibitors, anticancer activity, tumor microenvironment, lipid rafts, protein prenylation, Ras signaling, tumor immunogenicity, mitochondrial respiration, chemosensitization, gemcitabine, 5-fluorouracil, oxaliplatin, adjuvant therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review. https://app.cochat.ai/papers/10.3389/fphar.2026.1815366
The paper
Pîntea, A.-I., Croitoru, A. E., Dinu-Pîrvu, C. E., & Dima, S. O. (2026). The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2026.1815366

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.